Curis to Present at Upcoming 30th Annual SNO Meeting

On November 14, 2025 Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, reported that Curis will report emavusertib and BTKi clinical data in Primary CNS Lymphoma (PCNSL) and Secondary CNS Lymphoma (SCNSL) in three presentations and preclinical data on emavusertib in an oral presentation at the 30th Annual Meeting of the Society for Neuro-Oncology (SNO) on November 19-23:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

November 21, 2025 – 4:30 PM ET (11:30 AM HT)

Format:

Poster Presentation

Presenter:

Dr. Christian Grommes, Memorial Sloan Kettering Cancer Center, NY, NY

Title:

Analysis of Genetic Mutation Profile and CNS Pharmacokinetics in Relapsed/Refractory Primary CNS Lymphoma Patients Responding to Novel Emavusertib (IRAK4i) and BTKi Combination

Format:

Poster Presentation

Presenter:

Dr. Lakshmi Nayak, Dana-Farber Cancer Institute, Boston, MA

Title:

Preliminary Safety and Efficacy of Emavusertib (CA-4948) in Combination with Ibrutinib in Relapsed/Refractory Primary Central Nervous System Lymphoma Patients

November 22, 2025 – 4:45 PM ET (11:45 AM HT)

Format:

Rapid Oral Presentation

Presenter:

Dr. Christian Grommes, Memorial Sloan Kettering Cancer Center, NY, NY

Title:

Analysis of Genetic Mutation Profile and CNS Pharmacokinetics in Relapsed/Refractory Primary CNS Lymphoma Patients Responding to Novel Emavusertib (IRAK4i) and BTKi Combination

Format:

Poster Presentation

Presenter:

Cecilia A. Merrigan, APRN, CNP, DNP, Mayo Clinic, Rochester, MN

Title:

Promising Efficacy Signal in Secondary CNS Lymphoma Patients Treated with Emavusertib and Ibrutinib

November 23, 2025 – 3:24 PM ET (10:24 AM HT)

Format:

Oral Presentation

Presenter:

Christina von Roemeling, Ph.D., University of Florida, Gainesville, FL

Title:

Targeting Myddosome Signaling to Improve Immunotherapy in Melanoma Brain Metastases

(Press release, Curis, NOV 14, 2025, View Source [SID1234659967])